EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to support a proactive approach

Petra Denig, Peter J C Stuijt

Expert Review of Clinical Pharmacology · 2024

DOI: 10.1080/17512433.2024.2378765 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2024. Verfasst von Petra Denig und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Deprescriptions, Caregivers, Cardiovascular Diseases. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: For people with type 2 diabetes and/or cardiovascular conditions, deprescribing of glucose-lowering, blood pressure-lowering and/or lipid-lowering medication is recommended when they age, and their health status deteriorates. So far, deprescribing rates of these so-called cardiometabolic medications are low. A review of challenges and interventions addressing these challenges in this population is pertinent. AREAS COVERED: We first provide an overview of relevant deprescribing recommendations. Next, we review challenges for healthcare providers (HCPs) to deprescribe cardiometabolic medication and provide insight in the patient and caregiver perspective on deprescribing. We summarize findings from research on implementing deprescribing of cardiometabolic medication and reflect on strategies to enhance deprescribing. We have used a combination of methods to search for relevant articles. EXPERT OPINION: There is a need for rigorous development and evaluation of intervention strategies aimed at proactive deprescribing of cardiometabolic medication. To address challenges at different levels, these should be multifaceted interventions. All stakeholders must become aware of the relevance of deintensifying medication in this population. Education and training for HCPs and patients should support patient-centered communication and shared decision-making. Development of procedures and tools to select eligible patients and conduct targeted medication reviews are important for implementation of deprescribing in routine care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2DeprescriptionsCaregiversCardiovascular DiseasesHealth PersonnelHypoglycemic AgentsHumansAgedAge Factors

Stichwörter der Autor:innen

Cardiometabolic risk factorsdeprescribingdiabetes mellitus type 2implementation sciencemedication reviewolder adultspatient-centered careshared decision-making

Substanzen

Hypoglycemic Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.

Zitieren

APA

Denig, P., & Stuijt, P. J. C. (2024). Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to support a proactive approach. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2024.2378765

Vancouver

Denig P, Stuijt PJC. Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to support a proactive approach. Expert Review of Clinical Pharmacology. 2024. doi:10.1080/17512433.2024.2378765

BibTeX
@article{Denig2024,
  author = {Denig, Petra and Stuijt, Peter J C},
  title = {Perspectives on deprescribing in older people with type 2 diabetes and/or cardiovascular conditions: challenges from healthcare provider, patient and caregiver perspective, and interventions to support a proactive approach},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2024},
  doi = {10.1080/17512433.2024.2378765}
}
Kostenlos starten →